Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

Abstract To investigate the efficacy and safety of osimertinib plus savolitinib for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and de novo MET aberrations, we conducted a randomized, multicenter, open-label, phase 2 study (Clinica...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Anna Li, Wei-Neng Feng, Juan Li, Bing-Fei Xu, Jun Zhao, Yun Jia, Ke-Jing Tang, Yong-Sheng Li, Cheng-Zhi Zhou, Yun Fan, Chong-Rui Xu, Yue-Li Sun, Hua-Jun Chen, Hong-Hong Yan, Zong-Kun Shi, Jin-Ji Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2026-01-01
coleção:	Nature Communications
Acesso em linha:	https://doi.org/10.1038/s41467-025-67950-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!